134
Participants
Start Date
February 1, 2017
Primary Completion Date
September 30, 2024
Study Completion Date
February 28, 2027
Ruxolitinib Oral Tablet [Jakafi]
Ruxolitinib will be administered on days 1-28 of the treatment cycle.
Lenalidomide
Lenalidomide will be administered on Days 1-21 of the treatment cycle.
Methylprednisolone
Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
ACTIVE_NOT_RECRUITING
Regional Cancer Care Associates (RCCA) MD, LLC, Bethesda
RECRUITING
Cancer Specialists, LLC, Jacksonville
TERMINATED
Millennium Oncology Research Clinic, Pembroke Pines
RECRUITING
James R. Berenson M.D. Inc., West Hollywood
RECRUITING
Wellness Oncology and Hematology, West Hills
RECRUITING
Global Oncology, Inc., Alhambra
RECRUITING
California Cancer Associates for Research & Excellence (cCARE), Encinitas
TERMINATED
Compassionate Care Research Group, Inc., Fountain Valley
TERMINATED
Robert A. Moss, M.D., F.A.C.P., Inc., Fountain Valley
TERMINATED
Sansum Clinic- Ridley-Tree Cancer Center, Santa Barbara
TERMINATED
Pacific Cancer Care, Monterey
WITHDRAWN
Northwest Medical Specialists, PPLC, Tacoma
ACTIVE_NOT_RECRUITING
Comprehensive Blood and Cancer Center, Bakersfield
Lead Sponsor
Collaborators (1)
Incyte Corporation
INDUSTRY
Oncotherapeutics
INDUSTRY